^
Association details:
| Biomarker: | ROS1 positive + TP53 positive |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P2.14-02 - TP53 Mutations Affect Sensitivity to Lorlatinib in ROS1 Positive NSCLC: Final Results of the PFROST Trial
Published date:
07/12/2022
Excerpt:
Co-altered ROS1+/TP53+ individuals were mainly females (54.5%), never smokers (54.5%), with median age of 57 years and PS of 1 (63.6%). In this subgroup, RR was 27.3%, median PFS was 8.5 months (95% CI: 0.8-16.2) and median OS was 14.6 months (95% CI: 0-31.1), respectively.
